About Seqens
Seqens is a company based in Ecully (France) founded in 2003 was acquired by SK Capital in December 2021. The company has 39 employees as of April 07, 2024. Seqens has completed 2 acquisitions, including CELLforCURE and CU Chemie Uetikon. Seqens offers products and services including APIs and Intermediates, Personal Care Ingredients, and Custom Specialty Ingredients. Seqens operates in a competitive market with competitors including Almac Group, Indoco Remedies, Concord Biotech, BDR Pharmaceuticals Internationals and Aurobindo Pharma, among others.
- Headquarter Ecully, France
- Employees 39 as on 07 Apr, 2024
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Monolom India Pharma Private Limited
- Date of Incorporation 27 Oct, 2017
- Jurisdiction Pune, Maharashtra, India
-
Annual Revenue
$1.87 M (USD)19.92as on Mar 31, 2022
-
Net Profit
$183.32 K (USD)21.7as on Mar 31, 2022
-
EBITDA
$551.88 K (USD)1.58as on Mar 31, 2022
-
Latest Funding Round
Not available
-
Investors
Eurazeo
& 4 more
-
Employee Count
39
as on Apr 07, 2024
-
Investments & Acquisitions
CELLforCURE
& 1 more
-
Acquired by
SK Capital
(Dec 17, 2021)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Seqens
Seqens offers a comprehensive portfolio of products and services, including APIs and Intermediates, Personal Care Ingredients, and Custom Specialty Ingredients.
Manufacture generic and custom active pharmaceutical ingredients for industry use.
Wide range of ingredients for personal care market applications.
High-quality specialized chemical products for various applications.
People of Seqens
Unlock access to complete
Funding Insights of Seqens
Investors in Seqens
Seqens has secured backing from 5 investors, including venture fund investors. Prominent investors backing the company include Eurazeo, Societe Generale Capital Partenaire and Merieux Developement.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments are managed by Societe Generale Capital Partenaire.
|
Locked | Locked | Locked | |
|
Private equity and debt investments are managed across multiple sectors.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Seqens
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Seqens
Seqens has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include CELLforCURE and CU Chemie Uetikon.
Investment portfolio details for Seqens
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Develops innovative technologies for cell and gene therapy products to advance medical treatments.
|
Locked | Locked | 2010 | Locked | |
|
Organic chemicals and pharmaceutical APIs are manufactured and distributed.
|
Locked | Locked | 1970 | Locked |
Complete acquisition details for Seqens
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Seqens
Detailed financials for Seqens
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Seqens Comparisons
Peer comparison for Seqens
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Seqens
Seqens operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Almac Group, Indoco Remedies, Concord Biotech, BDR Pharmaceuticals Internationals and Aurobindo Pharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Integrated CDMO services for biopharma R&D and manufacturing are offered.
|
|
| Locked | Locked | Locked |
APIs manufacturing and formulation services are provided in therapeutic segments.
|
|
| Locked | Locked | Locked |
APIs and enzymes are manufactured through fermentation by the CDMO.
|
|
| Locked | Locked | Locked |
APIs and finished products are developed and manufactured.
|
|
| Locked | Locked | Locked |
Generic biocatalytic solutions are provided for pharmaceutical applications.
|
|
| Locked | Locked | Locked |
APIs and peptides are developed and manufactured by Asymchem.
|
Detailed competitors of Seqens
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Seqens
Complete news archive for Seqens
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Seqens
Seqens was founded in 2003 and raised its 1st funding round 13 years after it was founded.
Seqens is headquartered in Ecully, France. It is registered at Ecully, Auvergne-rhone-alpes, France.
As of Apr 07, 2024, the latest employee count at Seqens is 39.
Annual revenue of Seqens is $1.87M as on Mar 31, 2022.
Seqens was established in 2003 in Ecully, France, as a provider of contract manufacturing services within the pharmaceutical and chemical sectors. Operations focus on the production of small molecules and peptides for clients seeking outsourced manufacturing solutions. Services encompass development, scale-up, and commercial production, with facilities supporting global supply chains. The company operates primarily from European locations, emphasizing regulatory compliance and quality standards in its processes.
Seqens's top competitors include Concord Biotech, BDR Pharmaceuticals Internationals and Almac Group.
Seqens offers APIs and Intermediates, Personal Care Ingredients, and Custom Specialty Ingredients.
Seqens has made 2 acquisitions, including CELLforCURE, and CU Chemie Uetikon.
Seqens has 5 investors. Key investors include Eurazeo, Societe Generale Capital Partenaire, Merieux Developement, Ardian, and SK Capital.